Bristol Myers Squibb and Bain Capital Establish a new Company for Autoimmune Diseases

The company will start with five potential treatments for autoimmune diseases that it has licensed from Bristol Myers Squibb. Bristol Myers Squibb will retain 20% of the shares in the new company. Bristol Myers Squibb and Bain Capital have teamed up to create a new, independent biopharmaceutical company focused on developing innovative therapies for autoimmune diseases. This partnership represents a significant step in the pharmaceutical industry as it combines Bristol Myers Squibb's scientific expertise with Bain Capital's financial strength...